Toxicological characteristic of novel antitumour multitargeted agent anthrafuran


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. One of the modern approaches to development of antitumor drugs is based on oriented search of specific tumor cells molecular targets inhibitors. The application of such therapeutic agents will improve selectivity of action and decrease side effects of antineoplastic therapy. Novel antitumor multitargeted drug anthrafuran (LCTA-2034), obtained in Gause Institute of new antibiotics, represents a derivative of anthra[2,3-b]furan-3-carboxamide. Compound exhibits pronounced antitumor activity in vivo. Objective. The objective of the present study was to investigate the toxicity of LCTA-2034. Materials and methods. Toxicological study was performed in male outbred rats. The drug was administrated intraperitoneally at the total doses of MTD and LD50 (14 x 3 mg/kg or 14 x 4.5 mg/kg with 24-h interval). Dynamics of body weight, hematological parameters, blood biochemical parameters, electrocardiography and urinalysis were performed for all animals. 5 animals in each group were sacrificed 1 and 30 days post treatment. The mass coefficients of heart, kidneys, liver, spleen and thymus were calculated. The internal organs were subjected to histological evaluation. Results. The results of the study demonstrate that the intraperitoneal injections of LCTA-2034 don't produce any changes in examined clinical-laboratory parameters. The treatment with LCTA-2034 in total dose of MTD had no effect on morphological structure of the internal organs of rats. The reversible structural damages in liver, kidneys and small intestine were found in group of rats, treated with high dose of the drug. Signs of cardiotoxicity were documented by microscopic pathology observation on day 30 post treatment in individual animals. Conclusion. Dose dependence and reversibility of toxic effects of LCTA-2034 allows us to recommend it to further advance.

About the authors

E. R. Pereverzeva

Gause Institute of new antibiotics

Author for correspondence.
Russian Federation

M. I. Treschalin

Gause Institute of new antibiotics

Email: idtivan@yandex.ru
Russian Federation

N. V. Eremkin

Gause Institute of new antibiotics

Russian Federation

A. E. Shchekotikhin

Gause Institute of new antibiotics

Russian Federation

I. D. Treschalin

Gause Institute of new antibiotics

Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c)



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-53039 от  04.03.2013.